Carmel Pharma Introduces PhaSeal® Secondary Set (C60)
New Component Streamlines Safe Spiking, Priming and IV Bag Infusion with Hazardous Drugs
Columbus, OH, November 01, 2009 --(PR.com)-- Carmel Pharma, maker of the PhaSeal System for the safe handling of hazardous drugs, now offers the Secondary Set (C60) for safe, streamlined preparation and administration of IV bag infusions.
For safety and ease of use, the non-vented Secondary Set offers the following features:
· Drip chamber (20 drops/mL)
· Flow stop to facilitate priming of the Secondary Set from the bag prior to adding the drug
· Universal spike with built-in PhaSeal Connector for safe, leakproof transfer of the drug to the IV bag
· DEHP-free PVC tubing (40 in.)
For more information or to order, call 866-487-9250 or visit www.PhaSeal.com.
PhaSeal is more than a system for the safe handling of hazardous drugs. It’s the only clinically proven closed-system drug transfer device (CSTD) available today and is validated by more than 10 independent, peer-reviewed, published clinical studies. Distinguished by prominent thought leaders as the “Gold Standard” in safe handling, PhaSeal’s airtight Expansion Chamber and leakproof Double Membrane connections prevent exposure to hazardous drugs, including aerosols and vapors, and make it the only system that meets the National Institute for Occupational Safety and Health (NIOSH) and International Society of Oncology Pharmacy Practitioners (ISOPP) definition of a true CSTD. Its streamlined design and universally-compatible components make the system easy to use from preparation and administration to waste disposal.
The PhaSeal System is manufactured by Carmel Pharma AB in Gothenburg, Sweden and is distributed from its U.S. affiliate office, Carmel Pharma, Inc., in Columbus, OH. PhaSeal has been in use in the United States since 1998 and implemented in more than 1000 cancer facilities, infusion centers and private practices, including M.D. Anderson and Texas Children’s in Houston, TX; City of Hope in Duarte, CA; Dana Farber Cancer Institute in Boston, MA; SwedishAmerican Hospital in Rockford, IL; and Johns Hopkins University in Baltimore, MD, just to name a few. For more information on Carmel Pharma or the PhaSeal System, please visit www.phaseal.com or email info@carmelpharmausa.com. To request additional product details, high-resolution imagery, story ideas and expert references, or to learn more about the topic of safe handling from today’s clinical thought leaders, please visit www.carmelpharmausa.com/media or contact Emily Frydendal at 614-318-2635 or emily.frydendal@carmelpharma.com.
###
For safety and ease of use, the non-vented Secondary Set offers the following features:
· Drip chamber (20 drops/mL)
· Flow stop to facilitate priming of the Secondary Set from the bag prior to adding the drug
· Universal spike with built-in PhaSeal Connector for safe, leakproof transfer of the drug to the IV bag
· DEHP-free PVC tubing (40 in.)
For more information or to order, call 866-487-9250 or visit www.PhaSeal.com.
PhaSeal is more than a system for the safe handling of hazardous drugs. It’s the only clinically proven closed-system drug transfer device (CSTD) available today and is validated by more than 10 independent, peer-reviewed, published clinical studies. Distinguished by prominent thought leaders as the “Gold Standard” in safe handling, PhaSeal’s airtight Expansion Chamber and leakproof Double Membrane connections prevent exposure to hazardous drugs, including aerosols and vapors, and make it the only system that meets the National Institute for Occupational Safety and Health (NIOSH) and International Society of Oncology Pharmacy Practitioners (ISOPP) definition of a true CSTD. Its streamlined design and universally-compatible components make the system easy to use from preparation and administration to waste disposal.
The PhaSeal System is manufactured by Carmel Pharma AB in Gothenburg, Sweden and is distributed from its U.S. affiliate office, Carmel Pharma, Inc., in Columbus, OH. PhaSeal has been in use in the United States since 1998 and implemented in more than 1000 cancer facilities, infusion centers and private practices, including M.D. Anderson and Texas Children’s in Houston, TX; City of Hope in Duarte, CA; Dana Farber Cancer Institute in Boston, MA; SwedishAmerican Hospital in Rockford, IL; and Johns Hopkins University in Baltimore, MD, just to name a few. For more information on Carmel Pharma or the PhaSeal System, please visit www.phaseal.com or email info@carmelpharmausa.com. To request additional product details, high-resolution imagery, story ideas and expert references, or to learn more about the topic of safe handling from today’s clinical thought leaders, please visit www.carmelpharmausa.com/media or contact Emily Frydendal at 614-318-2635 or emily.frydendal@carmelpharma.com.
###
Contact
Carmel Pharma, Inc.
Emily Frydendal
614-318-2635
www.carmelpharma.com
Emily Frydendal
614-318-2635
www.carmelpharma.com
Contact
Categories